$76.9 Million is the total value of Alerce Investment Management, L.P.'s 6 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ANNX | ANNEXON INC | $24,837,204 | -8.6% | 7,056,024 | 0.0% | 32.31% | -10.0% | |
AMWL | AMERICAN WELL CORPcl a | $21,999,006 | -11.0% | 10,475,717 | 0.0% | 28.62% | -12.4% | |
AKBA | AKEBIA THERAPEUTICS INC | $14,827,684 | +63.3% | 16,205,119 | 0.0% | 19.29% | +60.8% | |
AADI BIOSCIENCE INC | $11,154,877 | -5.5% | 1,630,830 | 0.0% | 14.51% | -7.0% | ||
ASMB | ASSEMBLY BIOSCIENCES INC | $2,561,625 | +36.8% | 2,227,500 | 0.0% | 3.33% | +34.7% | |
AILERON THERAPEUTICS INC | $1,486,534 | +44.4% | 830,466 | 0.0% | 1.93% | +42.1% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
AMERICAN WELL CORP | 12 | Q3 2023 | 62.9% |
ANNEXON INC | 12 | Q3 2023 | 35.9% |
AKEBIA THERAPEUTICS INC | 12 | Q3 2023 | 31.6% |
ASSEMBLY BIOSCIENCES INC | 12 | Q3 2023 | 8.7% |
AADI BIOSCIENCES INC | 9 | Q3 2023 | 24.1% |
AILERON THERAPEUTICS INC | 8 | Q3 2022 | 14.4% |
GLOBAL BLOOD THERAPEUTICS IN | 8 | Q3 2022 | 23.4% |
AILERON THERAPEUTICS INC | 4 | Q3 2023 | 2.3% |
AERPIO PHARMACEUTICALS INC | 3 | Q2 2021 | 5.2% |
View Alerce Investment Management, L.P.'s complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-09 |
13F-HR | 2024-02-09 |
13F-HR | 2023-11-13 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-04 |
13F-HR | 2022-05-13 |
13F-HR | 2022-02-09 |
View Alerce Investment Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.